194 filings
Page 5 of 10
6-K
qch11qreee5wses
28 Mar 23
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
9:05am
6-K
axoco3y7
23 Mar 23
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
8:53am
6-K
75z4t js3
22 Mar 23
Current report (foreign)
4:45pm
6-K
b62fpb p80e
24 Feb 23
Current report (foreign)
4:45pm
6-K
q1xvvv
6 Feb 23
Current report (foreign)
4:45pm
6-K
8ut7qt0bfyvgdm2 wq3
2 Feb 23
Notice of Extraordinary General Meeting
4:45pm
6-K/A
agf1n
20 Jan 23
Current report (foreign) (amended)
4:45pm
6-K
bc09rbo
19 Jan 23
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
8:45am
6-K
gx60ry0v31jk3ox
29 Dec 22
Current report (foreign)
5:00pm
6-K
dsk 5kwvux77zx7ltzt7
27 Dec 22
Current report (foreign)
5:17pm
6-K/A
kz1mdb7jp25g0itkn
27 Dec 22
Current report (foreign) (amended)
7:22am
6-K/A
1o5 5ejnj8aht1zidhl
27 Dec 22
Current report (foreign) (amended)
7:21am
6-K/A
4w3rtm
27 Dec 22
Current report (foreign) (amended)
7:16am
6-K
eoewroo6nq7e fu
6 Dec 22
Current report (foreign)
6:00am
6-K
yaomcf
5 Dec 22
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
10:44am
6-K
nh7ymlhfr
14 Nov 22
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
7:21am
6-K
qgs czeqsg3s4
10 Nov 22
Evaxion CEO comments on strategic focus
6:00am
6-K
b0o 0pqbl
4 Oct 22
Current report (foreign)
8:56am
424B5
z2bmkca
4 Oct 22
Prospectus supplement for primary offering
8:52am
6-K
32os mwa90d6
23 Sep 22
Current report (foreign)
8:18am